Endoscopic and Mucosal Healing in Crohns Disease with Azathioprine

doi:10.4328/jcam.4726

Mo1668 Mucosal Healing is a Cost-Effective Endpoint With Biologic Therapy in Crohns Disease - Results From a Decision Analysis

Gastroenterology ◽

10.1016/s0016-5085(12)62523-2 ◽

2012 ◽

Vol 142 (5) ◽

pp. S-654 ◽

Cited By ~ 1

Author(s):

Ashwin N. Ananthakrishnan ◽

Joshua R. Korzenik ◽

Chin Hur

Keyword(s):

Decision Analysis ◽

Biologic Therapy ◽

Cost Effective ◽

Mucosal Healing ◽

Crohns Disease

Get full-text (via PubEx)

Der neurotrophe Serotoninrezeptoragonist SR 57746A fördert mucosal healing und verhindert mucosale Läsionen im Intestinaltrakt

Zeitschrift für Gastroenterologie ◽

10.1055/s-0033-1352674 ◽

2013 ◽

Vol 51 (08) ◽

Author(s):

M Porzner ◽

J Walldorf ◽

M Hermann ◽

G Joodi ◽

JH Niess ◽

...

Keyword(s):

Mucosal Healing

Get full-text (via PubEx)

Learning curve in mucosal healing (MH) and inflammatory activity assessment by using the Erlangen MH score for confocal laser endomicroscopy (eMHs) in inflammatory bowel diseases

Zeitschrift für Gastroenterologie ◽

10.1055/s-0034-1386260 ◽

2014 ◽

Vol 52 (08) ◽

Author(s):

G Hundorfean ◽

MT Chiriac ◽

A Nägel ◽

H Albrecht ◽

C Janson ◽

...

Keyword(s):

Learning Curve ◽

Inflammatory Bowel Diseases ◽

Mucosal Healing ◽

Inflammatory Activity ◽

Confocal Laser Endomicroscopy ◽

Confocal Laser ◽

Activity Assessment ◽

Bowel Diseases ◽

Inflammatory Bowel

Get full-text (via PubEx)

Development of a new scoring system for assessment of mucosal healing in IBD by using the newly introduced BLI (Blue Light Imaging) technology

10.1055/s-0037-1605197 ◽

2017 ◽

Author(s):

H Neumann ◽

H Neumann Sen ◽

F Rahman ◽

F Thieringer ◽

P Galle

Keyword(s):

Blue Light ◽

Scoring System ◽

Mucosal Healing ◽

Imaging Technology ◽

New Scoring

Get full-text (via PubEx)

AZATHIOPRINE AND ENDOSCOPIC MUCOSAL HEALING: ABOUT A SERIES OF 67 CASES

10.1055/s-0038-1637566 ◽

2018 ◽

Author(s):

FZ Chabib ◽

I Benelbarhdadi ◽

FZ Ajana

Keyword(s):

Mucosal Healing

Get full-text (via PubEx)

Overview of Biological Therapy in Ulcerative Colitis: Current and Future Directions

Journal of Gastrointestinal and Liver Diseases ◽

10.15403/jgld.2014.1121.242.bezz ◽

2015 ◽

Vol 24 (2) ◽

pp. 203-213 ◽

Cited By ~ 9

Author(s):

Federica Furfaro ◽

Cristina Bezzio ◽

Sandro Ardizzone ◽

Alessandro Massari ◽

Roberto De Franchis ◽

...

Keyword(s):

Ulcerative Colitis ◽

Immunosuppressive Agents ◽

Mucosal Healing ◽

Aminosalicylic Acid ◽

Proinflammatory Mediators ◽

Experimental Drugs ◽

New Treatments ◽

Aggressive Clinical Course ◽

Near Future

The treatment of ulcerative colitis (UC) has changed over the last decade. It is extremely important to optimize the therapies which are available nowadays and commonly used in daily clinical practice, as well as to stimulate the search for more powerful drugs for the induction and maintenance of sustained and durable remission, thus preventing further complications. Therefore, it is mandatory to identify the patients' prognostic variables associated with an aggressive clinical course and to test the most potent therapies accordingly.To date, the conventional therapeutic approach based on corticosteroids, salicylates (sulfasalazine, 5-aminosalicylic acid) or immunosuppressive agents is commonly used as a first step to induce and to maintain remission. However, in recent years, knowledge of new pathogenetic mechanisms of ulcerative colitis have allowed us to find new therapeutic targets leading to the development of new treatments that directly target proinflammatory mediators, such as TNF-alpha, cytokines, membrane migration agents, cellular therapies.The aim of this review is to provide the most significant data regarding the therapeutic role of drugs in UC and to give an overview of biological and experimental drugs that will become available in the near future. In particular, we will analyse the role of these drugs in the treatment of acute flare and maintenance of UC, as well as its importance in mucosal healing and in treating patients at a high risk of relapse.

Get full-text (via PubEx)